Luminex Will Be Acquired By DiaSorin For About $1.8Bn

 
• By Marion Webb

The buyout will broaden DiaSorin’s positioning in the fast-growing molecular diagnostics space and expand Luminex’s foothold outside the US.

ESB Professional

Italian diagnostics company DiaSorin agreed to buy Luminex for about $1.8bn in an all-cash transaction.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business